A vision for the surgical management of papillary thyroid carcinoma: Extensive lymph node compartmental dissections and selective use of radioiodine

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 4, 2009, Pages 1086-1088

  Mazzafern, Ernest L ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN;

CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; EDITORIAL; HIGH RISK POPULATION; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; NEOPLASM; PAPILLARY CARCINOMA; PRIORITY JOURNAL; THYROID CARCINOMA; THYROIDECTOMY;

EID: 65249093831     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0298     Document Type: Editorial

References (21)

1. Links TP, Van Tol KM, Jager PL, Plukker JT, Piers DA, Boezen HM, Dullaart RP, de Vries EG, Sluiter WJ 2005 Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr Relat Cancer 12:273-280
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 83:2638-2648
3. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167
4. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Sturgeon C 2007 Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 246:375-384
5. Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH 2003 Papillary micro- carcinoma of the thyroid: prognostic significance of lymph node metastasis and multifocality. Cancer 98:31-40
6. Pereira JA, Jimeno J, Miquel J, Iglesias M, Munnté A, Sancho JJ, Sitges-Serra A 2005 Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery 138:1095-1100
7. Podnos YD, Smith D, Wagman LD, Ellenhorn JD 2005 The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg 71:731-734
8. Zaydfudim V, Feurer ID, Griffin MR, Phay JE 2008 The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery144:1070-1077
9. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM; The American Thyroid Association Guidelines Taskforce 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16: 109 -142
10. Shimamoto K, Satake H, Sawaki A, Ishigaki T, Funahashi H, Imai T 1998 Preoperative staging of thyroid papillary carcinoma with ultrasonography. Eur J Radiol 29:4-10
11. White ML, Doherty GM, Gauger PG 2008 Evidence-based surgical management of substernal goiter. World J Surg 32:1285-1300
12. Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, Ito K, Takami H, Takanashi Y 2003 Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 237:399-407
13. Mirallie E, Visset J, Sagan C, Hamy A, Le Bodic MF, Paineau J 1999 Localization of cervical node metastasis of papillary thyroid carcinoma. World J Surg 23:970-973
14. Machens A, Hinze R, ThomuschO,DralleH 2002 Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 26:22-28
15. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC 2004 Clinical review 170: a systematic review and metaanaly- sis of the effectiveness of radioactive iodine remnant ablation for well- differentiated thyroid cancer. J Clin Endocrinol Metab 89:3668 -3676
16. Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, Straus S, Goldstein DP 2008 An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 37:457-480, x
17. Ron E 2008 Concise review: treatment for thyroid cancer as a risk factor for a second malignancy. Clin Thyroidol (online) 20(2):3-4. http://thyroid.org/ professionals/publications/clinthy/clinthy-v202.pdf
18. Rubino C, De Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M 2003 Second primary malignancies in thyroid cancer patients. Br J Cancer 89:1638 -1644
19. deVathaireF2008 The carcinogenic effects of radioiodine therapy forthyroid carcinoma. Nat Clin Pract Endocrinol Metab 4:180-181
20. Remy H, BorgetI, Leboulleux S, Guilabert N, LavielleF, Garsi J,BournaudC, Gupta S, Schlumberger M, Ricard M 2008 131IEffectivehalf-life and dosim- etry in thyroid cancer patients. J Nucl Med 49:1445-1450
21. Bonnet S, Hartl D, Leboulleux S, Baudin E, Lumbroso JD, Al Ghuzlan A, Chami L, Schlumberger M, Travagli JP 2009 Prophylactic Lymph Node Dissection for Papillary Thyroid Cancer Less than 2 cm: Implications for Radio- iodine Treatment. J Clin Endocrinol Metab 94:1162-1167